VIDEO: Results of AMPLIFY trial ‘biggest splash’ for front-line treatment of CLL

ByCory Perla

Fact checked byMindy Valcarcel, MS

SAN DIEGO —In this video, Jennifer A. Woyach, MD, discusses results from the AMPLIFY trial, presented at ASH Annual Meeting and Exhibition.

The trial evaluated fixed-duration acalabrutinib (Calquence, AstraZeneca) plus venetoclax (Venclexta, AbbVie) with or without obinutuzumab (Gazyva, Genentech) versus chemoimmunotherapy as front-line treatment for chronic lymphocytic leukemia.

“This is a really important study because it hopefully will lead to FDA approval of one or two of these combinations that are either an all-oral regimen or our first triplet regimen," Woyach, professor in the division of hematology at The Ohio State University, said.

Reference:

Brown JR, et al. Abstract 1009. Presented at: ASH Annual Meeting and Exhibition; Dec. 7-10, 2024; San Diego.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Woyach reports serving in consulting roles for AstraZeneca, AbbVie, Genentech, Janssen, Loxo Lilly, Merck, Newave Pharmaceutical, Pharmacyclics and Schrödinger.